- Market Capitalization, $K 5,973
- Shares Outstanding, K 882
- Annual Sales, $ 2,950 K
- Annual Income, $ -13,370 K
- 60-Month Beta 0.78
- Price/Sales 1.95
- Price/Cash Flow N/A
- Price/Book 3.15
|Period||Period Low||Period High||Performance|
| || |
-0.82 (-10.19%)since 09/13/19
| || |
-0.02 (-0.21%)since 07/12/19
| || |
-31.82 (-81.58%)since 10/12/18
OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company's Acuitas AMR Gene Panel and Acuitas Lighthouse Software for the detection of urinary tract...
OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas AMR Gene Panel and Acuitas Lighthouse Software will be presented during IDWeek 2019, taking place October 2-6 in Washington, D.C. at...
OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On September 16, 2019, Curetis, N.V. announced that its wholly-owned...
-- Combined company to be headquartered in Gaithersburg, MD, USA
Revenue up 28% Quarter-over-Quarter
OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its second quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, August 7, 2019. OpGen's management...
Collaborator data demonstrating OpGen's rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -24.24% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance for its Acuitas AMR Gene Panel test for the detection of...
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.